Thus two structurally related compounds (CsnB/TMPA) exhibit inverse activities on metabolic disease, and it is possible that the prodiabetic activity of CsnB may be due to other modes of action, such as enhancement of NR4A1 nuclear export. This evidence concerns the gene NR4A1 and metabolic disease.